Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berry Leaf Extract
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Effects of Berry Leaf Extract on Cognitive Processing in Healthy Elderly Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Berry Leaf Extract
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coriander Seed Oil
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Coriander Seed Oil
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Wheat Polar Lipid Complex
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Efficacy of Two Dietary Supplements Claiming Anti-aging Properties
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Wheat Polar Lipid Complex
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coriander Seed Oil
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessement of the Soothing Effect of a Food Supplement on Sensitive and Reactive Skin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 14, 2023
Lead Product(s) : Coriander Seed Oil
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berry Extract
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Anti-aging Efficacy of Two Dietary Supplements
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Berry Extract
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Wheat Polar Lipid Complex
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Efficacy of Two Dietary Supplements on Hair Loss and Hair Aspect
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Wheat Polar Lipid Complex
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Wheat Polar Lipid Complex
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : Wheat Polar Lipid Complex
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Engineered SARS-CoV-2-RBD-Fc Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : AKS-452 is a protein subunit vaccine that is in Phase II testing at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : Engineered SARS-CoV-2-RBD-Fc Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Extramel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Bionov
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 15, 2013
Lead Product(s) : Extramel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Bionov
Deal Size : Inapplicable
Deal Type : Inapplicable